Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B HOLMBERG

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
The International Journal of Artificial Organs|July 29, 2006
Minimized weight gain between hemodialysis contributes to a reduced risk of deathB G Stegmayr, M Brannstrom, S Bucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Scandinavian Journal of Urology and Nephrology|December 29, 2007
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint studyB G Stegmayr, M Brännström, S Bucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
British Journal of Cancer|June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMFM Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
The International Journal of Artificial Organs|July 29, 2006
Minimized weight gain between hemodialysis contributes to a reduced risk of deathB G Stegmayr, M Brannstrom, S Bucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Scandinavian Journal of Urology and Nephrology|December 29, 2007
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint studyB G Stegmayr, M Brännström, S Bucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
British Journal of Cancer|June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMFM Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 13